Mettler-Toledo International Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. The company supplies precision instruments and related services for laboratory, industrial, retail, logistics and other markets. Financial statements are unaudited and prepared under U.S. GAAP; amounts below are in U.S. dollars.
Financial performance
| Metric | Q3 2020 | Q3 2019 | First nine months 2020 | First nine months 2019 |
|---|---|---|---|---|
| Net sales | $807.4 million | $753.9 million | $2,147.2 million | $2,164.7 million |
| Gross profit / margin | $469.6 million / 58.2% | $435.1 million / 57.7% | $1,242.0 million / 57.8% | $1,242.9 million / 57.4% |
| Earnings before taxes | $205.8 million | $169.4 million | $479.6 million | $450.3 million |
| Net earnings | $161.8 million | $129.4 million | $386.4 million | $368.4 million |
| Diluted EPS | $6.68 | $5.20 | $15.92 | $14.67 |
- Q3 sales rose 7% in U.S. dollars and 6% in local currencies; net earnings increased about 25%. Nine-month sales declined 1% in U.S. dollars and were flat in local currencies, while net earnings rose about 5%.
- Q3 operating performance benefited from higher sales volume, favorable price realization, temporary cost savings and material-cost reductions. These benefits were partly offset by higher transportation costs and unfavorable business mix. Product gross margin declined to 59.7% from 60.2%; service gross margin improved to 52.7% from 48.9%.
- Nine-month operating cash flow was $473.8 million, versus $401.7 million. Capital expenditures were $57.4 million, versus $71.6 million; operating cash flow less capital expenditures was approximately $416.4 million, versus $330.1 million.
- At September 30, cash and equivalents were $153.7 million; total debt was $1,224.2 million, including $55.1 million current and $1,169.1 million long-term. The company reported $700.7 million of additional borrowing availability under its credit agreement and compliance with debt covenants. Current assets were $1,046.3 million and current liabilities $764.1 million.
- During the first nine months, the company repurchased $400.0 million of stock (475,530 shares), compared with $558.7 million in the prior-year period. Shares outstanding at September 30 were 23.8 million.
Material changes and operating trends
- Q3 demand improved in most businesses and regions, with particularly strong growth in China and laboratory-related products. China external-customer sales increased 16% in U.S. dollars; the company cited 17% local-currency growth in China overall.
- Laboratory sales rose 11% in U.S. dollars in Q3 and 2% for the nine-month period. Industrial sales increased 2% in Q3 but fell 3% year to date; retail sales increased 8% in Q3 but fell 7% year to date.
- For the first nine months, COVID-19-related lower customer demand weighed on sales across regions. Nine-month segment profit increased overall to $547.9 million from $521.8 million, but Chinese Operations’ segment profit declined 4% in U.S. dollars.
- Amortization increased to $42.0 million for the nine months from $36.9 million; interest expense increased to $29.1 million from $27.8 million. Restructuring charges declined to $7.3 million from $11.1 million.
Outlook, risks and unusual items
- The filing provides no specific full-year revenue or earnings guidance. Management said it remained cautious: the pandemic and global economic uncertainty could reduce customer demand in future quarters, and the effects on results and financial condition could be material.
- Management said production and logistics facilities were operating, supply-chain interruption was minimal, and the company was supporting customers through on-site and remote service. Temporary cost measures included reduced work hours, salary freezes and voluntary senior-leadership salary reductions.
- The board authorized an additional $2.5 billion for the share repurchase program in November 2020, after quarter-end. The filing reported $933.4 million of remaining program availability at September 30, before that authorization.
- Currency movements remain a risk. The company estimated that a 1% strengthening of the Swiss franc against the euro could reduce annual pretax earnings by about $1.6–$1.8 million; a 1% weakening of the renminbi against the U.S. dollar could reduce them by about $1.8–$2.0 million.
- Restructuring charges were $4.6 million in Q3 and $7.3 million year to date, primarily employee-related. Management did not expect pending legal proceedings, including environmental matters, to have a material adverse effect. No material legal proceedings were listed in Part II.
Important facts for investors to verify
- Whether the Q3 demand recovery continued, particularly in China and laboratory products, and how COVID-19 affected subsequent-period sales and customer collections.
- Whether margin improvement from pricing, cost controls and material savings was sustainable, given transportation costs and product mix.
- Debt, available credit and cash generation relative to planned repurchases, potential acquisitions and expected $10–$15 million of net manufacturing-facility investments over the next two years.
- The size and timing of future repurchases following the November authorization, and the effect on share count and liquidity.
- Foreign-exchange exposure, debt currency effects, and the reported derivative liabilities of $18.7 million at quarter-end.